IL10 and campylobacteriosis: Whereas placebo-treated human-gut-microbiota-associated IL-10−/− mice were suffering from severe campylobacteriosis, carvacrol treatment resulted in improved clinical conditions as early as 5 days p.i., particularly in less severe bloody diarrhea despite the high pathogenic burdens in the large intestines.